{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-224116","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2024-09-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.875237+00:00","generated_at":"2026-05-31T02:04:10.604655+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Wave Life Sciences reports positive interim Phase 2 data for WVE-N531: adjusted dystrophin 9.0% in DMD exon 53","bullets":["Mean muscle content-adjusted dystrophin expression 9.0% (range 4.6-13.9%); unadjusted 5.5% (range 3.3-8.3%) in ambulatory boys.","Dystrophin isoforms consistent with milder Becker DMD; 89% of ambulatory participants achieved ≥5% adjusted dystrophin.","WVE-N531 safe and well tolerated; all treatment-related AEs mild, no serious AEs or discontinuations.","Muscle concentration ~41,000 ng/g; 61-day half-life supports monthly dosing; preclinical data suggest higher concentration in heart/diaphragm.","Wave expects regulatory feedback and complete 48-week FORWARD-53 data in 1Q 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-224116","json":"https://secwatch.observer/filing/0001193125-24-224116.json","markdown":"https://secwatch.observer/filing/0001193125-24-224116.md","text":"https://secwatch.observer/filing/0001193125-24-224116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312524224116/0001193125-24-224116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312524224116/d876211d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:04:10.604655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}